These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12941750)

  • 1. Unilateral edema due to a thiazolidinedione.
    Bell DS
    Diabetes Care; 2003 Sep; 26(9):2700. PubMed ID: 12941750
    [No Abstract]   [Full Text] [Related]  

  • 2. Thiazolidinedione-induced edema in patients with heart failure.
    Stroup JS
    Am J Health Syst Pharm; 2007 Dec; 64(23):2426-30; author reply 2430. PubMed ID: 18029947
    [No Abstract]   [Full Text] [Related]  

  • 3. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications.
    Mudaliar S; Chang AR; Henry RR
    Endocr Pract; 2003; 9(5):406-16. PubMed ID: 14583425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuation of thiazolidinedione therapy in patients without left ventricular dysfunction who developed edema and congestive-heart-failure symptoms.
    Wang F; Vergara C; Carabino J; Desilets A; Vasquez R
    Am J Health Syst Pharm; 2004 Aug; 61(15):1604-8. PubMed ID: 15372837
    [No Abstract]   [Full Text] [Related]  

  • 5. Rosiglitazone-induced anasarca without heart failure: capillary leakage?
    Dagdelen S; Kurt M; Aydin K; Bayraktar M
    Hormones (Athens); 2008; 7(2):180-3. PubMed ID: 18477557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiazolidinediones and macular edema: comment on "Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes".
    Singh S; Segal JB
    Arch Intern Med; 2012 Jul; 172(13):1011-3. PubMed ID: 22688825
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of rosiglitazone-induced edema: two case reports and a review of the literature.
    Wang F; Aleksunes LM; Reagan LA; Vergara CM
    Diabetes Technol Ther; 2002; 4(4):505-14. PubMed ID: 12396745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus.
    Colucciello M
    Arch Ophthalmol; 2005 Sep; 123(9):1273-5. PubMed ID: 16157815
    [No Abstract]   [Full Text] [Related]  

  • 9. Thiazolidinediones and fluid retention.
    Kiryluk K; Isom R
    Kidney Int; 2007 Sep; 72(6):762-8. PubMed ID: 17637710
    [No Abstract]   [Full Text] [Related]  

  • 10. [Heart failure with thiazolidinedione treatment: what do we know today?].
    Erdmann E
    Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.
    Aubert RE; Herrera V; Chen W; Haffner SM; Pendergrass M
    Diabetes Obes Metab; 2010 Aug; 12(8):716-21. PubMed ID: 20590749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute pulmonary edema due to rosiglitazone use in a patient with diabetes mellitus.
    Cekmen N; Cesur M; Cetinbas R; Bedel P; Erdemli O
    J Intensive Care Med; 2006; 21(1):47-50. PubMed ID: 16698744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
    Nesto RW; Bell D; Bonow RO; Fonseca V; Grundy SM; Horton ES; Le Winter M; Porte D; Semenkovich CF; Smith S; Young LH; Kahn R; ;
    Circulation; 2003 Dec; 108(23):2941-8. PubMed ID: 14662691
    [No Abstract]   [Full Text] [Related]  

  • 14. Thiazolidinedione-associated congestive heart failure and pulmonary edema.
    Jamieson A; Abousleiman Y
    Mayo Clin Proc; 2004 Apr; 79(4):571; author reply 575-7. PubMed ID: 15065625
    [No Abstract]   [Full Text] [Related]  

  • 15. Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
    Bailey SD; Xie C; Do R; Montpetit A; Diaz R; Mohan V; Keavney B; Yusuf S; Gerstein HC; Engert JC; Anand S;
    Diabetes Care; 2010 Oct; 33(10):2250-3. PubMed ID: 20628086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mild, reversible pancytopenia induced by rosiglitazone.
    Maaravi Y; Stessman J
    Diabetes Care; 2005 Jun; 28(6):1536. PubMed ID: 15920093
    [No Abstract]   [Full Text] [Related]  

  • 17. [Heart failure while taking glitazones--what do we know today?].
    Halbritter R
    Dtsch Med Wochenschr; 2009 Jul; 134(28-29):1488; author reply 1488. PubMed ID: 19572255
    [No Abstract]   [Full Text] [Related]  

  • 18. The rise and fall of rosiglitazone: reply.
    Slaoui M
    Eur Heart J; 2010 May; 31(10):1282-4. PubMed ID: 20499440
    [No Abstract]   [Full Text] [Related]  

  • 19. [Doubts as to the cardiovascular safety of rosiglitazone].
    Hoekstra JB; Bossuyt PM; de Vries JH
    Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1449-50. PubMed ID: 17633972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between plasma hANP level and pretibial edema by pioglitazone treatment.
    Kahara T; Takamura T; Misaki T; Sakurai M; Takeshita Y; Shimizu A; Kaneko S
    Endocr J; 2005 Jun; 52(3):373-6. PubMed ID: 16006733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.